Proteome Sciences PLC (LSE:PRM) — Market Cap & Net Worth
Market Cap & Net Worth: Proteome Sciences PLC (PRM)
Proteome Sciences PLC (LSE:PRM) has a market capitalization of $71.69K (GBX589.22 Million) as of May 2, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31054 globally and #1151 in its home market, demonstrating a 30.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Proteome Sciences PLC's stock price GBX1.68 by its total outstanding shares 350724912 (350.72 Million). Analyse PRM cash generation efficiency to see how efficiently the company converts income to cash.
Proteome Sciences PLC Market Cap History: 2015 to 2026
Proteome Sciences PLC's market capitalization history from 2015 to 2026. Data shows change from $666.77K to $71.69K (-19.94% CAGR).
Index Memberships
Proteome Sciences PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.08 Million | 0.01% | #384 of 722 |
Weight: Proteome Sciences PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Proteome Sciences PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Proteome Sciences PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Proteome Sciences PLC's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $666.77K | $1.88 Million | -$2.72 Million | 0.35x | N/A |
| 2016 | $234.70K | $2.74 Million | -$2.28 Million | 0.09x | N/A |
| 2017 | $133.35K | $3.38 Million | -$2.50 Million | 0.04x | N/A |
| 2018 | $102.42K | $3.05 Million | -$1.31 Million | 0.03x | N/A |
| 2019 | $125.46K | $4.63 Million | $149.00K | 0.03x | 0.84x |
| 2020 | $165.14K | $4.71 Million | $295.00K | 0.04x | 0.56x |
| 2021 | $218.70K | $5.12 Million | $72.00K | 0.04x | 3.04x |
| 2022 | $149.36K | $7.78 Million | $1.32 Million | 0.02x | 0.11x |
| 2023 | $193.31K | $5.03 Million | -$2.44 Million | 0.04x | N/A |
| 2024 | $145.09K | $4.89 Million | -$3.41 Million | 0.03x | N/A |
Competitor Companies of PRM by Market Capitalization
Companies near Proteome Sciences PLC in the global market cap rankings as of May 2, 2026.
Key companies related to Proteome Sciences PLC by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Proteome Sciences PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Proteome Sciences PLC's market cap moved from $666.77K to $ 71.69K, with a yearly change of -19.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX71.69K | -32.80% |
| 2025 | GBX106.68K | -26.47% |
| 2024 | GBX145.09K | -24.94% |
| 2023 | GBX193.31K | +29.43% |
| 2022 | GBX149.36K | -31.71% |
| 2021 | GBX218.70K | +32.43% |
| 2020 | GBX165.14K | +31.63% |
| 2019 | GBX125.46K | +22.50% |
| 2018 | GBX102.42K | -23.20% |
| 2017 | GBX133.35K | -43.18% |
| 2016 | GBX234.70K | -64.80% |
| 2015 | GBX666.77K | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Proteome Sciences PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.69K USD |
| MoneyControl | $71.69K USD |
| MarketWatch | $71.69K USD |
| marketcap.company | $71.69K USD |
| Reuters | $71.69K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more